| Literature DB >> 30567570 |
Alfredo Guillén-Del-Castillo1, Carmen Pilar Simeón-Aznar2, Eduardo L Callejas-Moraga3, Carles Tolosa-Vilella3, Serafín Alonso-Vila1, Vicente Fonollosa-Pla1, Albert Selva-O'Callaghan1.
Abstract
BACKGROUND: To determine whether lung involvement is related to microvascular perturbations, nailfold videocapillaroscopy (NVC) was performed in patients with systemic sclerosis (SSc).Entities:
Keywords: Interstitial lung disease; Nailfold videocapillaroscopy; Pulmonary hypertension; Scleroderma; Systemic sclerosis
Mesh:
Year: 2018 PMID: 30567570 PMCID: PMC6299957 DOI: 10.1186/s13075-018-1775-9
Source DB: PubMed Journal: Arthritis Res Ther ISSN: 1478-6354 Impact factor: 5.156
Fig. 1Quantitative nailfold videocapillaroscopy: a normal capillaries; b enlarged capillaries (solid arrows) and microhaemorrhage (dashed arrow); c giant capillaries (solid arrows) and microhaemorrhages (dashed arrows); d tortuous capillaries (solid arrows); e capillaries with neoangiogenesis as ramified capillaries (solid arrows); f capillaries with neoangiogenesis as disorganized capillaries (solid arrows)
Demographic, clinical and immunological characteristics of the patients with SSc (n = 134, 100%)
| Variable | Result |
|---|---|
| Age at SSc onset (years) | 38.5 (± 15.7) |
| Age at NVC (years) | 54.7 (± 14.4) |
| Cutaneous subsets, dcSSc/lcSSc/ssSSc | 28 (20.9)/88 (65.7)/18 (13.4) |
| Time elapsed from first symptom to NVC (years) | 16.0 (± 12.6) |
| Time elapsed from first non-RP symptom to NVC (years) | 10.9 (± 9.9) |
| 2013 ACR/EULAR SSc classification criteria fulfilment | 121 (90.2) |
| ACA/ATA/anti-RNA pol III/anti-PM/Scl | 49 (36.6)/31 (23.1)/14 (10.4)/11 (8.2) |
| Raynaud’s phenomenon | 132 (98.5) |
| Telangiectasias | 97 (72.4) |
| Digital ulcers | 62 (46.3) |
| Calcinosis | 29 (21.6) |
| Scleroderma renal crisis | 2 (1.5) |
| Interstitial lung disease | 58 (43.3) |
| Pulmonary arterial hypertension | 11 (8.2) |
| Cardiac involvement | 103 (76.9) |
| Musculoskeletal disease | 40 (29.9) |
| Gastrointestinal involvement | 110 (82.1) |
| Overlap features | 19 (14.1) |
Data presented as mean (± standard deviation) for continuous variables and as number (%) for categorical variables
SSc systemic sclerosis, NVC nailfold videocapillaroscopy, dcSSc diffuse cutaneous systemic sclerosis, lcSSc limited cutaneous systemic sclerosis, ssSSc sine scleroderma systemic sclerosis, RP Raynaud’s phenomenon, ACR American College of Rheumatology, EULAR European League Against Rheumatism, ACA anticentromere antibodies, ATA anti-topoisomerase I
Pulmonary function test and echocardiography within a 3-month period of nailfold videocapillaroscopy
| Variable |
| Result |
|---|---|---|
| Pulmonary function test | ||
| FVC, % predicted | 134 | 80.8 (± 20.1) |
| DLCO, % predicted | 134 | 66.2 (± 23.7) |
| FVC%/DLCO% | 134 | 1.5 (± 0.4) |
| Echocardiography | ||
| RVSP (mmHg) | 96 | 30.7 (± 12.0) |
| TRV (m/s) | 96 | 2.8 (± 0.3) |
| TRV ≥ 2.9 m/s or other echo PH signs | 134 | 14 (10.4) |
Data presented as mean (± standard deviation) for continuous variables and as number (%) for categorical variables
FVC forced vital capacity, DLCO diffusion capacity of the lung for carbon monoxide, RVSP right ventricular systolic pressure, TRV tricuspid regurgitation velocity, PH pulmonary hypertension
Nailfold videocapillaroscopy characteristics and comparisons between groups of patients depending on pulmonary involvement
| ILD comparisons | PAH comparisons | |||||
|---|---|---|---|---|---|---|
| ILD ( | No ILD ( | PAH ( | No PAH ( | |||
| Quantitative NVC features | ||||||
| Capillary density ( | 4.86 (4.14–5.80) | 5.88 (4.74–6.85) | 0.005* | 5.47 (5.00–5.83) | 5.42 (4.31–6.74) | 0.997 |
| Enlarged capillaries ( | 0.84 (0.31–1.53) | 0.85 (0.39–1.58) | 0.738 | 0.56 (0.25–0.93) | 0.91 (0.40–1.61) | 0.128 |
| Giant capillaries ( | 0.26 (0.00–0.64) | 0.30 (0.04–1.07) | 0.362 | 0.06 (0.00–0.40) | 0.29 (0.03–1.02) | 0.167 |
| Microhaemorrhages ( | 0.12 (0.00–0.38) | 0.13 (0.00–0.42) | 0.735 | 0.06 (0.00–0.22) | 0.14 (0.00–0.40) | 0.101 |
| Tortuous capillaries ( | 0.45 (0.19–1.31) | 0.72 (0.28–1.49) | 0.216 | 0.63 (0.25–1.71) | 0.59 (0.23–1.43) | 0.773 |
| Neoangiogenesis ( | 0.56 (0.23–1.28) | 0.31 (0.12–0.62) | 0.005* | 0.70 (0.47–1.80) | 0.33 (0.12–0.78) | 0.007* |
| Qualitative NVC features | ||||||
| Cutolo’s pattern, early/active/late | 8 (13.8)/23 (39.7)/23 (39.7) | 15 (19.7)/36 (47.4)/14 (18.4) | 0.366/0.373/0.006* | 1 (9.1)/4 (36.4)/6 (54.5) | 21 (17.9)/52 (44.4)/29 (24.8) | 0.688/0.755/0.069 |
Data presented as median (interquartile range) for continuous variables and as number (%) for categorical variables
ILD interstitial lung disease, PAH pulmonary arterial hypertension, NVC nailfold videocapillaroscopy
ªAdjusted by each millimetre of the nailfold
*Statistically significant comparison after Bonferroni correction (p < 0.008)
Association between qualitative nailfold videocapillaroscopy and pulmonary function tests
| Cutolo’s pattern | |||||
|---|---|---|---|---|---|
| Normal ( | Early ( | Active ( | Late ( | ||
| FVC, % predicted | 89.1 (± 20.3) | 82.3 (± 17.2) | 85.3 (± 18.3) | 69.6 (± 20.7)*,** | 0.001 |
| DLCO, % predicted | 77.3 (± 20.8) | 71.4 (± 27.5) | 68.6 (± 20.4) | 54.2 (± 23.3)*,†,‡ | 0.002 |
Data presented as mean (± standard deviation) for continuous variables
FVC forced vital capacity, DLCO diffusion capacity of the lung for carbon monoxide
*p < 0.01, late versus normal
**p = 0.001, late versus active
†p < 0.05, late versus early
‡p < 0.05, late versus active
Inter-observer and intra-observer reliability
| Inter-observer (95% CI) | Intra-observer (95% CI) | |
|---|---|---|
| ICC for quantitative NVC features | ||
| Capillary density | 0.96 (0.93–0.98) | 0.97 (0.93–0.98) |
| Enlarged capillaries | 0.87 (0.77–0.93) | 0.93 (0.83–0.97) |
| Giant capillaries | 0.91 (0.83–0.95) | 0.95 (0.90–0.97) |
| Microhaemorrhages | 0.97 (0.94–0.98) | 0.99 (0.98–0.99) |
| Tortuous capillaries | 0.92 (0.85–0.95) | 0.91 (0.69–0.96) |
| Neoangiogenesis | 0.77 (0.58–0.88) | 0.81 (0.56–0.90) |
| Cohen’s | ||
| Cutolo’s patterns | 0.83 (0.66–1.0) | 0.81 (0.64–0.97) |
| Normal pattern | 0.92 (0.75–1.0) | 0.83 (0.55–1.0) |
| Early pattern | 0.73 (0.42–1.0) | 0.66 (0.33–0.99) |
| Active pattern | 0.82 (0.65–0.99) | 0.87 (0.71–1.0) |
| Late pattern | 0.87 (0.69–1.0) | 0.81 (0.59–10) |
CI confidence interval, ICC intra-class coefficient, NVC nailfold videocapillaroscopy
Multiple regression analysis according to quantitative nailfold videocapillaroscopy
|
| 95% CI | ||
|---|---|---|---|
| FVC as dependent variable | |||
| Male gender | −11.0 | −19.2 to −2.9 | 0.008 |
| Interstitial findings on HRCT | −14.8 | −21.1 to −8.4 | < 0.001 |
| ACA positivity | 7.2 | 0.1 to 14.3 | 0.045 |
| Neoangiogenesis/mm | −7.3 | −11.0 to −3.6 | < 0.001 |
| DLCO as dependent variable | |||
| Digital ulcers | −6.7 | −13.6 to 0.1 | 0.056 |
| Interstitial findings on HRCT | −9.4 | −16.4 to −2.5 | 0.008 |
| FVC | 0.5 | 0.3 to 0.7 | <0.001 |
| PAH confirmed by RHC | −14.3 | −26.9 to −1.6 | 0.027 |
| TRV ≥ 2.9 m/s or other echo PH signs | −16.4 | − 28.3 to −4.6 | 0.007 |
| Enlarged capillaries | 7.8 | 1.1 to 14.4 | 0.021 |
| Giant capillaries | −11.8 | −21.4 to −2.2 | 0.016 |
Only variables with statistical significance or tendency to be significant are presented
B regression coefficient, CI confidence interval, FVC forced vital capacity, HRCT high resolution computed tomography, ACA anticentromere antibodies, DLCO diffusion capacity of the lung for carbon monoxide, PAH pulmonary arterial hypertension, RHC right heart catheterization, TRV tricuspid regurgitation velocity, PH pulmonary hypertension
Multiple regression analysis according to Cutolo’s patterns
|
| 95% CI | ||
|---|---|---|---|
| FVC as dependent variable | |||
| Male gender | −12.3 | −21.0 to −3.5 | 0.006 |
| Interstitial findings on HRCT | −13.5 | −20.2 to −6.7 | < 0.001 |
| ACA positivity | 8.6 | −0.1 to 17.4 | 0.051 |
| Cutolo’s late pattern | −14.3 | −26.1 to −2.5 | 0.018 |
| DLCO as dependent variable | |||
| Digital ulcers | −8.3 | −14.8 to −1.8 | 0.013 |
| Interstitial findings on HRCT | −9.8 | −16.8 to −2.8 | 0.006 |
| FVC | 0.5 | 0.3 to 0.7 | < 0.001 |
| PH confirmed by RHC | −14.1 | −26.8 to −1.5 | 0.028 |
| TRV ≥ 2.9 m/s or other echo PH signs | − 14.9 | −26.8 to −3.0 | 0.014 |
Only variables with statistical significance or tendency to be significant are presented
B regression coefficient, CI confidence interval, FVC forced vital capacity, HRCT high resolution computed tomography, ACA anticentromere antibodies, DLCO diffusion capacity of the lung for carbon monoxide, PAH pulmonary arterial hypertension, PH pulmonary hypertension, RHC right heart catheterization, TRV tricuspid regurgitation velocity